Eagle Rock Investment Company LLC Buys 14,084 Shares of IQVIA Holdings Inc. $IQV

Eagle Rock Investment Company LLC boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 30.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 60,416 shares of the medical research company’s stock after purchasing an additional 14,084 shares during the period. IQVIA accounts for about 1.9% of Eagle Rock Investment Company LLC’s investment portfolio, making the stock its 14th biggest holding. Eagle Rock Investment Company LLC’s holdings in IQVIA were worth $13,618,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in IQV. Leonard Rickey Investment Advisors P.L.L.C. boosted its holdings in shares of IQVIA by 3.3% in the 4th quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock valued at $409,000 after buying an additional 58 shares during the last quarter. JFS Wealth Advisors LLC increased its holdings in IQVIA by 17.3% during the fourth quarter. JFS Wealth Advisors LLC now owns 785 shares of the medical research company’s stock worth $177,000 after buying an additional 116 shares during the last quarter. Dakota Wealth Management raised its position in IQVIA by 48.2% during the fourth quarter. Dakota Wealth Management now owns 7,180 shares of the medical research company’s stock worth $1,618,000 after acquiring an additional 2,334 shares in the last quarter. Regatta Capital Group LLC lifted its stake in IQVIA by 7.0% in the fourth quarter. Regatta Capital Group LLC now owns 2,424 shares of the medical research company’s stock valued at $546,000 after acquiring an additional 158 shares during the last quarter. Finally, National Wealth Management Group LLC acquired a new stake in IQVIA in the fourth quarter valued at $755,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on IQV shares. Royal Bank Of Canada began coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective on the stock. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the stock from $174.00 to $213.00 in a report on Monday, March 9th. Citigroup lowered their price target on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. JPMorgan Chase & Co. dropped their price objective on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research note on Friday, February 6th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, IQVIA has an average rating of “Buy” and an average price target of $229.13.

IQVIA Price Performance

Shares of IQV opened at $164.08 on Friday. The company’s 50-day moving average is $186.70 and its 200-day moving average is $205.21. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The firm has a market capitalization of $27.84 billion, a PE ratio of 20.88, a PEG ratio of 1.64 and a beta of 1.39. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. During the same quarter in the previous year, the firm posted $3.12 EPS. IQVIA’s revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.